Experimental Biology 2008. Today's research: tomorrow's health.
Fisher
Hannah
H
Thomson Reuters, 77 Hatton Garden, London, EC1N 8JS, UK. hannah.fisher@thomsonreuters.com
D000818:Animals; D018926:Anti-Allergic Agents / Q000494:pharmacology / Q000627:therapeutic use; D053282:CD27 Ligand / Q000276:immunology; D019970:Cocaine-Related Disorders / Q000188:drug therapy; D003248:Constipation / Q000188:drug therapy; D016207:Cytokines / Q000037:antagonists & inhibitors; D004358:Drug Therapy / Q000639:trends*; D004791:Enzyme Inhibitors / Q000494:pharmacology; D004851:Epoxide Hydrolases / Q000037:antagonists & inhibitors; D006801:Humans; D007896:Leishmaniasis / Q000188:drug therapy; D001523:Mental Disorders / Q000188:drug therapy; D009422:Nervous System Diseases / Q000188:drug therapy; D010601:Pharmacology, Clinical / Q000639:trends*; D000081082:Phosphoinositide-3 Kinase Inhibitors; D053220:Receptors, TNF-Related Apoptosis-Inducing Ligand / Q000037:antagonists & inhibitors; D050916:TRPV Cation Channels / Q000037:antagonists & inhibitors
D018926:Anti-Allergic Agents; D053282:CD27 Ligand; D016207:Cytokines; D004791:Enzyme Inhibitors; D000081082:Phosphoinositide-3 Kinase Inhibitors; D053220:Receptors, TNF-Related Apoptosis-Inducing Ligand; D050916:TRPV Cation Channels; C494482:TRPV1 protein, human; D004851:Epoxide Hydrolases